Oragenics (NYSE:OGEN) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGENGet Rating) in a research note issued on Wednesday. The brokerage set a “hold” rating on the stock.

Shares of NYSE OGEN opened at $0.35 on Wednesday. The company has a market capitalization of $40.16 million, a PE ratio of -2.46 and a beta of 0.09. The firm’s fifty day moving average is $0.36. Oragenics has a 52-week low of $0.30 and a 52-week high of $1.15.

Oragenics (NYSE:OGENGet Rating) last released its quarterly earnings results on Thursday, March 24th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $0.09 million during the quarter.

Oragenics Company Profile (Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Recommended Stories

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.